Novartis Historical Balance Sheet

NVS Stock  USD 96.73  0.85  0.89%   
Trend analysis of Novartis AG ADR balance sheet accounts such as Total Current Liabilities of 22 B provides information on Novartis' total assets, liabilities, and equity, which is the actual value of Novartis AG ADR to its prevalent stockholders. By breaking down trends over time using Novartis balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Novartis AG ADR latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Novartis AG ADR is a good buy for the upcoming year.

Novartis Inventory

5.95 Billion

  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

About Novartis Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Novartis AG ADR at a specified time, usually calculated after every quarter, six months, or one year. Novartis Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Novartis and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Novartis currently owns. An asset can also be divided into two categories, current and non-current.

Novartis Balance Sheet Chart

Novartis Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Novartis AG ADR uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Novartis' Other Current Assets are comparatively stable compared to the past year. Accumulated Other Comprehensive Income is likely to gain to about 52.6 B in 2024, whereas Other Current Liabilities is likely to drop slightly above 11.4 B in 2024.

Total Assets

Total assets refers to the total amount of Novartis assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Novartis AG ADR books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Novartis balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Novartis AG ADR are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.
Most accounts from Novartis' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Novartis AG ADR current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
At this time, Novartis' Other Current Assets are comparatively stable compared to the past year. Accumulated Other Comprehensive Income is likely to gain to about 52.6 B in 2024, whereas Other Current Liabilities is likely to drop slightly above 11.4 B in 2024.
 2021 2022 2023 2024 (projected)
Short and Long Term Debt Total31.1B28.0B26.3B18.6B
Total Assets131.8B117.5B99.9B103.1B

Novartis balance sheet Correlations

0.710.660.780.920.780.520.710.920.920.290.97-0.280.120.7-0.07-0.26-0.010.890.77-0.050.00.880.430.410.55
0.710.850.880.390.180.170.90.450.630.580.630.290.420.38-0.4-0.470.180.910.64-0.15-0.530.940.220.50.73
0.660.850.960.360.180.040.70.390.740.610.50.070.60.26-0.42-0.520.390.740.680.16-0.660.860.270.750.61
0.780.880.960.50.360.110.750.520.830.580.66-0.030.460.4-0.36-0.470.210.840.740.15-0.50.940.340.660.77
0.920.390.360.50.90.650.430.990.830.070.92-0.46-0.050.710.12-0.08-0.080.660.65-0.060.310.620.420.260.28
0.780.180.180.360.90.460.280.840.76-0.120.84-0.63-0.340.710.290.09-0.320.530.590.060.480.480.450.020.23
0.520.170.040.110.650.460.120.690.350.170.55-0.36-0.120.230.10.01-0.260.330.12-0.210.330.260.230.04-0.07
0.710.90.70.750.430.280.120.490.610.170.70.220.160.45-0.25-0.370.140.90.68-0.14-0.40.880.110.230.62
0.920.450.390.520.990.840.690.490.820.110.92-0.380.00.70.07-0.13-0.050.70.65-0.120.240.650.410.270.27
0.920.630.740.830.830.760.350.610.820.290.88-0.410.110.65-0.12-0.31-0.010.790.760.14-0.10.840.590.430.49
0.290.580.610.580.07-0.120.170.170.110.290.110.250.650.02-0.45-0.370.130.380.17-0.07-0.460.480.280.710.5
0.970.630.50.660.920.840.550.70.920.880.11-0.33-0.130.740.02-0.17-0.20.870.71-0.10.150.820.460.160.49
-0.280.290.07-0.03-0.46-0.63-0.360.22-0.38-0.410.25-0.330.39-0.04-0.49-0.410.260.01-0.19-0.57-0.50.0-0.290.120.12
0.120.420.60.46-0.05-0.34-0.120.160.00.110.65-0.130.39-0.21-0.44-0.40.810.160.250.13-0.690.29-0.190.910.23
0.70.380.260.40.710.710.230.450.70.650.020.74-0.04-0.21-0.05-0.26-0.280.590.48-0.50.290.530.610.040.29
-0.07-0.4-0.42-0.360.120.290.1-0.250.07-0.12-0.450.02-0.49-0.44-0.050.96-0.06-0.2-0.090.110.72-0.28-0.25-0.35-0.27
-0.26-0.47-0.52-0.47-0.080.090.01-0.37-0.13-0.31-0.37-0.17-0.41-0.4-0.260.96-0.07-0.33-0.220.160.66-0.4-0.31-0.38-0.28
-0.010.180.390.21-0.08-0.32-0.260.14-0.05-0.010.13-0.20.260.81-0.28-0.06-0.07-0.020.250.22-0.50.08-0.420.67-0.06
0.890.910.740.840.660.530.330.90.70.790.380.870.010.160.59-0.2-0.33-0.020.7-0.14-0.250.970.320.350.68
0.770.640.680.740.650.590.120.680.650.760.170.71-0.190.250.48-0.09-0.220.250.70.19-0.160.750.270.470.53
-0.05-0.150.160.15-0.060.06-0.21-0.14-0.120.14-0.07-0.1-0.570.13-0.50.110.160.22-0.140.19-0.21-0.02-0.210.190.09
0.0-0.53-0.66-0.50.310.480.33-0.40.24-0.1-0.460.15-0.5-0.690.290.720.66-0.5-0.25-0.16-0.21-0.360.14-0.54-0.29
0.880.940.860.940.620.480.260.880.650.840.480.820.00.290.53-0.28-0.40.080.970.75-0.02-0.360.340.490.75
0.430.220.270.340.420.450.230.110.410.590.280.46-0.29-0.190.61-0.25-0.31-0.420.320.27-0.210.140.340.020.13
0.410.50.750.660.260.020.040.230.270.430.710.160.120.910.04-0.35-0.380.670.350.470.19-0.540.490.020.36
0.550.730.610.770.280.23-0.070.620.270.490.50.490.120.230.29-0.27-0.28-0.060.680.530.09-0.290.750.130.36
Click cells to compare fundamentals

Novartis Account Relationship Matchups

Novartis balance sheet Accounts

201920202021202220232024 (projected)
Total Assets118.4B132.1B131.8B117.5B99.9B103.1B
Short Long Term Debt Total29.3B38.0B31.1B28.0B26.3B18.6B
Other Current Liab15.4B17.5B18.0B17.2B15.1B11.4B
Total Current Liabilities28.3B33.1B30.2B28.7B26.4B22.0B
Total Stockholder Equity55.5B56.6B67.7B59.3B46.7B57.2B
Property Plant And Equipment Net13.7B13.9B13.1B12.2B10.9B13.5B
Current Deferred Revenue236M114M56M123M98M135.9M
Net Debt18.2B28.4B18.7B20.4B13.0B11.0B
Retained Earnings59.3B57.2B71.0B63.5B49.6B57.8B
Accounts Payable5.4B5.4B5.6B5.1B4.9B4.2B
Cash11.1B9.7B12.4B7.5B13.4B7.7B
Non Current Assets Total88.9B102.4B86.1B80.5B69.5B73.2B
Non Currrent Assets Other738M892M2.2B1.1B2.2B2.1B
Cash And Short Term Investments11.4B11.6B28.3B18.9B14.0B13.1B
Net Receivables8.6B8.5B8.3B8.3B9.4B8.8B
Common Stock Total Equity969M944M936M913M821.7M776.8M
Common Stock Shares Outstanding2.3B2.3B2.3B2.2B2.1B1.9B
Short Term Investments334M1.9B15.9B11.4B569M540.6M
Liabilities And Stockholders Equity118.4B132.1B131.8B117.5B99.9B103.1B
Non Current Liabilities Total34.6B42.3B33.8B29.4B26.8B23.6B
Inventory6.0B7.1B6.7B7.2B5.9B6.0B
Other Current Assets2.7B2.5B2.4B2.5B1.2B2.2B
Other Stockholder Equity(59.4B)(57.2B)(71.0B)(63.6B)(49.7B)(47.2B)
Total Liab62.8B75.4B64.0B58.0B53.2B45.6B
Property Plant And Equipment Gross13.7B13.9B13.1B12.2B22.8B14.0B
Total Current Assets29.5B29.7B45.7B36.9B30.5B29.9B
Short Term Debt7.3B10.1B6.6B6.2B6.3B6.3B
Common Stock936M913M901M890M825M767.6M
Accumulated Other Comprehensive Income54.6B55.7B66.8B58.5B45.9B52.6B
Intangible Assets28.8B36.8B34.2B31.6B26.9B22.4B
Other Liab12.5B14.4B9.2B7.6B8.7B8.5B
Other Assets14.8B14.7B12.4B4.8B5.6B10.1B
Long Term Debt20.4B26.3B22.9B20.2B18.4B12.8B
Good Will26.5B30.0B29.6B29.3B23.3B22.0B
Treasury Stock(69M)(80M)(53M)(48M)(55.2M)(58.0M)
Property Plant Equipment13.7B13.9B13.1B12.2B14.0B14.0B
Net Tangible Assets5.6B(5.5B)9.4B2.8B2.5B2.4B
Deferred Long Term Liab5.4B4.7B5.5B4.4B5.1B5.8B
Long Term Investments11.2B11.7B2.3B1.6B1.8B1.7B
Short Long Term Debt6.8B9.6B6.2B5.9B6.1B5.7B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Novartis AG ADR is a strong investment it is important to analyze Novartis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Novartis' future performance. For an informed investment choice regarding Novartis Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for Novartis Stock analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Equity Valuation
Check real value of public entities based on technical and fundamental data
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
4.987
Dividend Share
3.919
Earnings Share
4.1
Revenue Per Share
22.467
Quarterly Revenue Growth
0.074
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.